Thursday, 22 March 2012
AstraZeneca today announced that the High Court in the UK has rendered its opinion on the formulation patent protecting SEROQUEL XR® (quetiapine fumarate) prolonged-release tablets currently pending in the UK court. The court found the formulation patent protecting SEROQUEL XR (marketed as SEROQUEL XL in the UK) to be invalid. The patent was challenged by Accord Healthcare Limited, Intas Pharmaceuticals Limited, Hexal AG and Sandoz Limited, Teva UK Limited, and Teva Pharmaceutical Industries Limited.
This is the first court decision providing a determination that the SEROQUEL XR formulation patent is invalid. In the Netherlands on 7 March, the District Court in The Hague found the formulation patent protecting SEROQUEL XR to be valid. The High Court decision is limited to the UK and is not binding in other countries. AstraZeneca is engaged in numerous other proceedings regarding SEROQUEL XR related patents and regulatory exclusivity for SEROQUEL XR. In addition to the UK and the Netherlands, trials have concluded in the US and in Spain, and decisions are pending in those jurisdictions. Further updates will be provided on a quarterly basis as part of the Company’s earnings report.
AstraZeneca is disappointed with the court’s decision. However, the company remains committed to defending its intellectual property protecting SEROQUEL XR.
NOTES TO EDITORS
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com.
CONTACTS
Media Enquiries
Esra Erkal-Paler +44 20 7604 8030
Sarah Lindgreen +44 20 7604 8033
Investor Enquiries UK
James Ward-Lilley +44 20 7604 8122 mob: +44 7785 432613
Karl Hård +44 20 7604 8123 mob: +44 7789 654364
Nicklas Westerholm +44 20 7604 8124 mob: +44 7585 404950
Investor Enquiries US
Ed Seage +1 302 886 4065 mob: +1 302 373 1361
Jorgen Winroth +1 212 579 0506 mob: +1 917 612 4043